Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00148018
Status:
TERMINATED
Last Update Posted:
2008-07-10
First Post:
2005-09-01
Brief Title:
Study of Bortezomib Velcade in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkins Lymphoma
Sponsor:
University of Cologne
Organization:
University of Cologne
Study Overview
Official Title:
A Phase II Study of Bortezomib in Combination With Dexamethasone in Patients With Relapsed Hodgkins Lymphoma
Status:
TERMINATED
Status Verified Date:
2006-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to evaluate wether bortezomib and dexamethasone are active in patients with relapsed Hodgkins lymphoma
Detailed Description:
The proteasome-inhibitor bortezomib Velcade shows promising activity in various human lymphoma cell line In addition several studies in heavily pretreated patients with lymphoma showed also promising results
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None